Boster Bio Expands IHC Services for Time-Sensitive Tissue Research

PLEASANTON, CA, UNITED STATES, October 27, 2026 /CourierPR/ -- Boster Bio, a company founded in 1993 and based in Pleasanton, California, has highlighted its comprehensive IHC services to support time-sensitive tissue research. The firm offers access to over 3,000 validated immunohistochemistry (IHC) and immunofluorescence (IF) antibodies, along with automated tissue staining, digital imaging, and analysis. This service is designed to assist researchers who need support across the tissue staining workflow, particularly those facing publication, grant, or preclinical study deadlines.

Boster Bio's IHC and histology services encompass a range of tasks, including antibody selection, formalin-fixed, paraffin-embedded (FFPE) and frozen tissue processing, automated Leica Bond RX staining, and whole-slide imaging. Optional quantitative analysis or pathology review is also available. The company reviews the samples, targets, and deliverables before providing a project-specific turnaround estimate, rather than promising a fixed timeline for every study.

The success of IHC research depends on various factors, including sample condition, antibody suitability, antigen retrieval, controls, scanning, and analysis. These variables can affect the timing of results, making it crucial for researchers to plan their projects carefully. Boster Bio emphasizes the importance of antibody selection, noting that validation in one method, such as Western blot, does not guarantee similar performance in IHC. Researchers need to assess whether an antibody is suitable for the target species, tissue format, and intended application.

For projects with unfamiliar tissue types or targets, Boster Bio recommends discussing antibody availability and optimization requirements before submitting samples. This can help define the expected timeline and ensure that the project stays on track. The company supports FFPE tissue, frozen tissue, and formalin-fixed cell pellets, offering a comprehensive workflow that can include tissue preparation, antigen retrieval, and multiplex immunohistochemistry services.

Controls play a critical role in interpreting IHC results. Appropriate positive and negative controls help researchers assess whether the assay produces the expected staining pattern and whether background may affect interpretation. Boster Bio advises researchers to define controls, scoring criteria, and any quantitative endpoints before staining begins to facilitate more interpretable comparisons across samples or staining runs.

Researchers seeking a fast-turnaround IHC service can request a feasibility review, quote, and estimated schedule before sending samples. Boster Bio's service page provides detailed information on the required outputs, such as stained slides, whole-slide images, quantitative analysis, or pathology review. The company aims to help researchers meet tight deadlines, as evidenced by its assistance to a research group that needed to meet a two-week grant-data deadline.

Boster Bio's IHC, histology, and related assay services support biomarker research, preclinical studies, and translational tissue analysis. The company's offerings are designed to provide researchers with the tools and support they need to conduct time-sensitive tissue research efficiently and effectively.